A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Barbara De Moerloose; Nira Arad-Cohen; Daniel Cheuk; Jose Maria Fernandez Navarro; Henrik Hasle; Kirsi Jahnukainen; Gertjan J.L. Kaspers; Zhanna Kovalova; Birgitte Lausen; Ulrika Norén-Nyström; Josefine Palle; Ramune Pasauliene; Cornelis Jan Pronk; Kadri Saks; Anne Maria Tierens; Bernward Zeller; Jonas Abrahamsson

doi:10.1182/blood-2023-187251

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Barbara De Moerloose
, Nira Arad-Cohen
, Daniel Cheuk
, Jose Maria Fernandez Navarro
, Henrik Hasle
, Kirsi Jahnukainen
, Gertjan J.L. Kaspers
, Zhanna Kovalova
, Birgitte Lausen
, Ulrika Norén-Nyström
, Josefine Palle
, Ramune Pasauliene
, Cornelis Jan Pronk
, Kadri Saks
, Anne Maria Tierens
, Bernward Zeller
, Jonas Abrahamsson

Research output: Contribution to journal › Meeting Abstract › peer-review

7 Downloads (Pure)

Original language	English
Article number	831
Journal	Blood
Volume	142
Issue number	Suppl.1
DOIs	https://doi.org/10.1182/blood-2023-187251
Publication status	Published - 28 Nov 2023
Externally published	Yes
Event	ASH Annual Meeting - San Diego, United States Duration: 9 Dec 2023 → 12 Dec 2023 https://www.hematology.org/newsroom/annual-meeting-press/press-kit/general-annual-meeting-information-and-materials

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1182/blood-2023-187251

A Randomized Comparison of Liposomal DaunorubicinFinal published version, 460 KB

Cite this

De Moerloose, B., Arad-Cohen, N., Cheuk, D., Fernandez Navarro, J. M., Hasle, H., Jahnukainen, K., Kaspers, G. J. L., Kovalova, Z., Lausen, B., Norén-Nyström, U., Palle, J., Pasauliene, R., Pronk, C. J., Saks, K., Tierens, A. M., Zeller, B., & Abrahamsson, J. (2023). A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol. Blood, 142(Suppl.1), Article 831. https://doi.org/10.1182/blood-2023-187251

@article{6c88b4afac4e458fa60f45349f1c57f6,

title = "A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol",

author = "\{De Moerloose\}, Barbara and Nira Arad-Cohen and Daniel Cheuk and \{Fernandez Navarro\}, \{Jose Maria\} and Henrik Hasle and Kirsi Jahnukainen and Kaspers, \{Gertjan J.L.\} and Zhanna Kovalova and Birgitte Lausen and Ulrika Nor{\'e}n-Nystr{\"o}m and Josefine Palle and Ramune Pasauliene and Pronk, \{Cornelis Jan\} and Kadri Saks and Tierens, \{Anne Maria\} and Bernward Zeller and Jonas Abrahamsson",

year = "2023",

month = nov,

day = "28",

doi = "10.1182/blood-2023-187251",

language = "English",

volume = "142",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "Suppl.1",

note = "ASH Annual Meeting, ASH ; Conference date: 09-12-2023 Through 12-12-2023",

url = "https://www.hematology.org/newsroom/annual-meeting-press/press-kit/general-annual-meeting-information-and-materials",

}

De Moerloose, B, Arad-Cohen, N, Cheuk, D, Fernandez Navarro, JM, Hasle, H, Jahnukainen, K, Kaspers, GJL, Kovalova, Z, Lausen, B, Norén-Nyström, U, Palle, J, Pasauliene, R, Pronk, CJ, Saks, K, Tierens, AM, Zeller, B & Abrahamsson, J 2023, 'A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol', Blood, vol. 142, no. Suppl.1, 831. https://doi.org/10.1182/blood-2023-187251

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol. / De Moerloose, Barbara; Arad-Cohen, Nira; Cheuk, Daniel et al.
In: Blood, Vol. 142, No. Suppl.1, 831, 28.11.2023.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

AU - De Moerloose, Barbara

AU - Arad-Cohen, Nira

AU - Cheuk, Daniel

AU - Fernandez Navarro, Jose Maria

AU - Hasle, Henrik

AU - Jahnukainen, Kirsi

AU - Kaspers, Gertjan J.L.

AU - Kovalova, Zhanna

AU - Lausen, Birgitte

AU - Norén-Nyström, Ulrika

AU - Palle, Josefine

AU - Pasauliene, Ramune

AU - Pronk, Cornelis Jan

AU - Saks, Kadri

AU - Tierens, Anne Maria

AU - Zeller, Bernward

AU - Abrahamsson, Jonas

PY - 2023/11/28

Y1 - 2023/11/28

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:001159306703100

U2 - 10.1182/blood-2023-187251

DO - 10.1182/blood-2023-187251

M3 - Meeting Abstract

SN - 0006-4971

VL - 142

JO - Blood

JF - Blood

IS - Suppl.1

M1 - 831

T2 - ASH Annual Meeting

Y2 - 9 December 2023 through 12 December 2023

ER -

De Moerloose B, Arad-Cohen N, Cheuk D, Fernandez Navarro JM, Hasle H, Jahnukainen K et al. A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol. Blood. 2023 Nov 28;142(Suppl.1):831. doi: 10.1182/blood-2023-187251

A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this